Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2023 | ACU193 in Alzheimer’s disease: insights from the INTERCEPT AD study

Eric Siemers, MD, Acumen Pharmaceuticals, Charlottesville, VA, shares topline data from the Phase I first-in-human INTERCEPT AD study (NCT04931459), investigating ACU193 as a disease modifying therapy for Alzheimer’s disease (AD). ACU193 specifically targets the toxic soluble oligomers of amyloid-β (Aβ), hypothesized to be the primary pathological molecules in AD. The study assessed the safety and tolerability of ACU193, as well as its impact on biomarkers in the cerebrospinal fluid and blood. Notably, 5 out of 48 patients experienced amyloid-related imaging abnormalities (ARIA), a side-effect typically associated with antibodies targeting plaques. This finding suggests that ACU193 does influence plaques, which was confirmed by a subsequent PET scan analysis revealing a 20-25% plaque reduction among patients treated with ACU193. Other notable results from this study include the good target engagement of ACU193 to the oligomers across the patient cohort and a favorable safety profile. This interview took place at the Clinical Trials on Alzheimer’s Disease (CTAD) congress 2023 in Boston.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.